-Series A financing led by Sanofi Ventures with participation from Atlas Venture, Access Biotechnology, Vertex Ventures HC, Digitalis Ventures, Alexandria Venture Investments, and others CAMBRIDGE, ...

In a recent study posted to the bioRxiv* preprint server, researchers performed an extensive library docking for new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) ...

Terremoto Biosciences has launched with $75 million in series A financing to discover small-molecule drugs using its lysine-targeted covalency technology. Terremoto says most drugs that bind to ...

Misbehaving proteins are behind many diseases. One way drugmakers incapacitate these bad actors is to deploy molecules that bind to them. But finding solid footholds on the proteins to block their ...

Graphene oxide is composed of oxygenated functional groups, the most prevalent of which are carboxyl, carbonyl, epoxy, and hydroxyl. These functional groups present on graphe are polar, making it very ...

Although covalent drugs have been used for more than a century, the emergence of new tools has helped spur recent advances in the field. Indeed, covalent medicine experienced a resurgence roughly 15 ...

Matchpoint Therapeutics has been served $70 million in series A funds to fund its covalent molecule ambitions, prioritizing platform development and early discovery work. After raising $30 million in ...

Crystalline polymers assembled inside tumor cell lysosomes rupture membranes, release iron, and trigger immune-activating ...